Floatz logo

VORUCICLIB

Chronic Lymphocytic Leukemia (CLL)

MEI Pharma, Inc.Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Chronic Lymphocytic Leukemia (CLL) cohort.

Asset / SponsorPhaseRating
Immucillin H
BioCryst Pharmaceuticals
Phase 2B
IMMUNOGLOBULIN G2, ANTI-(HUMAN CD19 (ANTIGEN)) (SYNTHETIC HUMAN MONOCLONAL MEDI-551 HEAVY CHAIN), DISULFIDE WITH SYNTHETIC HUMAN MONOCLONAL MEDI-551 .KAPPA.-CHAIN, DIMER
MedImmune LLC
Phase 2B
Zoster Vaccine Recombinant, Adjuvanted
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2B
gsk2110183
University Health Network, Toronto
Phase 2B
Auranofin
University of Kansas Medical Center
Phase 2B

View all 34 →

Same molecule, other indications

VORUCICLIB is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
marginal zone lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
follicular lymphomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →